Diabetic kidney disease drives premature mortality among patients with type 1 diabetes. The role of age at diabetes onset is controversial. We analyzed risk for diabetic kidney disease according to age at onset of type 1 diabetes using follow-up of type 1 diabetic patients attending our tertiary referral center. 340 type 1 diabetic patients attending the Angers University Hospital in France between 1989 and 2000, were followed-up to 2018 or death. They were divided in tertiles of ages at type 1 diabetes onset: T1:1-13, T2:14-23, and T3: 24-40 years. The primary endpoint was first occurrence of macroalbuminuria (>300mg albumin/g creatinine), doubling of serum creatinine, estimated glomerular filtration rate (eGFR, CK-EPI formula) <60ml/min/1.73m2, end stage renal disease (ESRD), or all-cause death. Multivariate analyses were done. Of 114 T1 participants, 11 (9.6%) developed macroalbuminuria, 5 (4.4%) doubling of serum creatinine, 14 (12.3%) eGFR<60ml/min/1.73m2, 8 (7%) ESRD, and 14(12.3%) died. Of 119 T2 participants, 8 (.6.7%) developed macroalbuminuria, 1 (0.8%) doubling of serum creatinine, 7 (5.9%) eGFR<60ml/min/1.73m2, 4(3.3%) ESRD, and 15(12.6%) died. Of 114 T3 participants, 3 (2.8%) developed macroalbuminuria, 1 (0.93%) doubling of serum creatinine, 4 (3.7%) eGFR<60ml/min/1.73m2, none ESRD, and 31(29%) died. Using multivariate analysis, age<14years at type 1 diabetes onset increased risk for kidney disease: T1 vs. T2 HR=2.35(95% CI1.20-4.58), T1 vs. T3 HR=3.61(1.30-9.27), p<0.01.

Conclusions: Age <14 at type 1 diabetes onset was an independent risk factor for kidney disease in this >20-year monocentric follow-up study.


C. Carpentier: None. S. Dubois: None. Y. Abouleka: None. B. Duly-Bouhanick: Research Support; Self; Novo Nordisk A/S, Sanofi, Servier. S. Hadjadj: Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi, Servier. Research Support; Self; Bayer AG, Janssen Research & Development. Speaker's Bureau; Self; Abbott, Valbiotis. R. Coutant: None. R. Roussel: Advisory Panel; Self; Merck Sharp & Dohme Corp., Sanofi. Consultant; Self; Abbott, AstraZeneca, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Physiogenex. Research Support; Self; Janssen Pharmaceuticals, Inc. G. Velho: None. M. Marre: Advisory Panel; Self; Servier. Board Member; Self; Merck Sharp & Dohme Corp., Novo Nordisk A/S.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.